

# Pietschmann Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/66333/publications.pdf>

Version: 2024-02-01

171  
papers

17,912  
citations

27035

58  
h-index

15253

130  
g-index

183  
all docs

183  
docs citations

183  
times ranked

17291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sandacrabins – Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium**. Chemistry - A European Journal, 2022, 28, e202104484.	1.7	10
2	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 2022, 55, 341-354.e7.	6.6	21
3	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. Virus Evolution, 2022, 8, veac007.	2.2	10
4	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. Journal of Virology, 2022, 96, e0199521.	1.5	4
5	Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements. Journal of Virology, 2021, 95, .	1.5	13
6	Magnesium Complexes of Ladanein: A Beneficial Strategy for Stabilizing Polyphenolic Antivirals. European Journal of Inorganic Chemistry, 2021, 2021, 2764-2772.	1.0	1
7	Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes. Cells, 2021, 10, 3019.	1.8	10
8	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036830.	2.9	40
9	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE, 2020, 15, e0236447.	1.1	7
10	Liver-expressed <i>Cd302</i> and <i>Cr11</i> limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	4.7	23
11	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
12	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathogens, 2020, 16, e1008554.	2.1	25
13	Controlled Functional Zonation of Hepatocytes <i>In Vitro</i> by Engineering of Wnt Signaling. ACS Synthetic Biology, 2020, 9, 1638-1649.	1.9	13
14	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut, 2020, 69, 1659-1666.	6.1	18
15	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Research, 2020, 177, 104774.	1.9	30
16	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Medical Microbiology and Immunology, 2020, 209, 499-514.	2.6	6
17	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells, 2019, 8, 610.	1.8	5
18	HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells, 2019, 8, 233.	1.8	41

#	ARTICLE	IF	CITATIONS
19	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. <i>Viruses</i> , 2019, 11, 275.	1.5	7
20	Physicochemical Properties Govern the Activity of Potent Antiviral Flavones. <i>ACS Omega</i> , 2019, 4, 4871-4887.	1.6	11
21	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. <i>Journal of Hepatology</i> , 2019, 70, 1082-1092.	1.8	15
22	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019, 70, 593-602.	1.8	20
23	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. <i>Virus Research</i> , 2018, 248, 53-62.	1.1	124
24	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
25	CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. <i>Viruses</i> , 2018, 10, 207.	1.5	13
26	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. <i>PLoS Pathogens</i> , 2018, 14, e1007111.	2.1	46
27	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. <i>Antiviral Research</i> , 2017, 139, 129-137.	1.9	5
28	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. <i>Molecular and Cellular Proteomics</i> , 2017, 16, S75-S91.	2.5	53
29	Immune protection against reinfection with nonprimate hepacivirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2430-E2439.	3.3	42
30	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. <i>Journal of Hepatology</i> , 2017, 67, 480-489.	1.8	51
31	Virucidal Activity of World Health Organizationâ€œRecommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. <i>Journal of Infectious Diseases</i> , 2017, 215, 902-906.	1.9	151
32	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. <i>Antiviral Research</i> , 2017, 147, 19-28.	1.9	28
33	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
34	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. <i>ACS Macro Letters</i> , 2017, 6, 935-940.	2.3	4
35	Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
36	Flunarizine prevents hepatitis C virus membrane fusion in a genotypeâ€œdependent manner by targeting the potential fusion peptide within E1. <i>Hepatology</i> , 2016, 63, 49-62.	3.6	64

#	ARTICLE	IF	CITATIONS
37	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. <i>Cell Host and Microbe</i> , 2016, 20, 443-457.	5.1	46
38	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. <i>Journal of Virology</i> , 2016, 90, 10670-10681.	1.5	27
39	Hepatitis C virus plays hide and seek with neutralizing antibodies. <i>Hepatology</i> , 2016, 64, 1840-1842.	3.6	7
40	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. <i>Hepatology</i> , 2016, 64, 2274-2276.	3.6	7
41	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. <i>MBio</i> , 2016, 7, .	1.8	13
42	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2132-2139.	1.4	75
43	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. <i>Journal of Virology</i> , 2016, 90, 5075-5089.	1.5	4
44	Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. <i>Journal of Virology</i> , 2016, 90, 3065-3073.	1.5	22
45	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8 <sup>+</sup> T Cell Response by Selection of Altered Epitope Processing. <i>Journal of Virology</i> , 2016, 90, 33-42.	1.5	16
46	Decoding protein networks during virus entry by quantitative proteomics. <i>Virus Research</i> , 2016, 218, 25-39.	1.1	24
47	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. <i>Gut</i> , 2016, 65, 2029-2034.	6.1	21
48	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. <i>PLoS Pathogens</i> , 2016, 12, e1005568.	2.1	26
49	Hepatitis C Virus Stimulates Murine CD8 $\beta$ -Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. <i>PLoS Pathogens</i> , 2016, 12, e1005736.	2.1	4
50	Cell culture-derived HCV cannot infect synovial fibroblasts. <i>Scientific Reports</i> , 2015, 5, 18043.	1.6	1
51	Interferon $\alpha$ -inducible cholesterol $\alpha$ 25 $\beta$ -hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. <i>Hepatology</i> , 2015, 62, 702-714.	3.6	78
52	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , 2015, 7, 3995-4046.	1.5	42
53	Efficient Virus Assembly, but Not Infectivity, Determines the Magnitude of Hepatitis C Virus-Induced Interferon Alpha Responses of Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2015, 89, 3200-3208.	1.5	9
54	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. <i>Cell Reports</i> , 2015, 12, 864-878.	2.9	50

#	ARTICLE	IF	CITATIONS
55	Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. <i>Hepatology</i> , 2015, 61, 447-459.	3.6	116
56	Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons. <i>Journal of Virology</i> , 2015, 89, 3833-3845.	1.5	23
57	Mechanisms of Methods for Hepatitis C Virus Inactivation. <i>Applied and Environmental Microbiology</i> , 2015, 81, 1616-1621.	1.4	46
58	Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 532-543.	1.9	9
59	Sorafenib: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. <i>Journal of Hepatology</i> , 2015, 63, 813-821.	1.8	28
60	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. <i>Journal of General Virology</i> , 2015, 96, 2636-2642.	1.3	19
61	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. <i>PLoS ONE</i> , 2015, 10, e0134529.	1.1	30
62	A molecular tweezer antagonizes seminal amyloids and HIV infection. <i>ELife</i> , 2015, 4, .	2.8	71
63	In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. <i>Gut</i> , 2014, 63, 1375-1377.	6.1	2
64	Natural reservoirs for homologs of hepatitis C virus. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-9.	3.0	88
65	Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The keystones on a Peculiar Virion. <i>Viruses</i> , 2014, 6, 1149-1187.	1.5	56
66	A circuit of paracrine signals between liver sinusoid endothelial cells and hepatocytes regulates hepatitis C virus replication. <i>Hepatology</i> , 2014, 59, 363-365.	3.6	0
67	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. <i>Journal of Virology</i> , 2014, 88, 667-678.	1.5	2
68	The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets. <i>Digestive Diseases</i> , 2014, 32, 525-537.	0.8	3,128
69	Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. <i>PLoS ONE</i> , 2014, 9, e102235.	1.1	8
70	Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly. <i>Journal of Virology</i> , 2014, 88, 1433-1446.	1.5	88
71	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. <i>Hepatology</i> , 2014, 59, 78-88.	3.6	40
72	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. <i>Gut</i> , 2014, 63, 1137-1149.	6.1	148

#	ARTICLE	IF	CITATIONS
73	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with <i>in vitro</i> resistance to SR-BI-targeting agents. <i>Hepatology</i> , 2014, 60, 1508-1518.	3.6	50
74	Role of Hypervariable Region 1 for the Interplay of Hepatitis C Virus with Entry Factors and Lipoproteins. <i>Journal of Virology</i> , 2014, 88, 12644-12655.	1.5	42
75	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. <i>Antiviral Research</i> , 2014, 110, 52-59.	1.9	12
76	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , 2014, 60, 508-520.	3.6	7
77	Isolate-dependent use of claudins for cell entry by hepatitis C virus. <i>Hepatology</i> , 2014, 59, 24-34.	3.6	54
78	Entry and replication of recombinant hepatitis C viruses in cell culture. <i>Methods</i> , 2013, 59, 233-248.	1.9	46
79	Hepatitis C Virus Replication in Mouse Cells Is Restricted by IFN-Dependent and -Independent Mechanisms. <i>Gastroenterology</i> , 2013, 145, 1414-1423.e1.	0.6	30
80	Stability and transmission of hepatitis C virus in different anesthetic agents. <i>American Journal of Infection Control</i> , 2013, 41, 942-943.	1.1	3
81	Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. <i>EMBO Journal</i> , 2013, 32, 3055-3065.	3.5	177
82	Thermostability of seven hepatitis C virus genotypes <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Viral Hepatitis</i> , 2013, 20, 478-485.	1.0	17
83	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. <i>Current Hepatitis Reports</i> , 2013, 12, 200-213.	0.3	7
84	Anti-infective properties of epigallocatechin gallate (EGCG), a component of green tea. <i>British Journal of Pharmacology</i> , 2013, 168, 1059-1073.	2.7	415
85	Two pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood products. <i>Transfusion</i> , 2013, 53, 1010-1018.	0.8	54
86	Cell Culture Systems for Hepatitis C Virus. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 17-48.	0.7	72
87	Characterization of the inhibition of hepatitis C virus entry by <i>in vitro</i> -generated and patient-derived oxidized low-density lipoprotein. <i>Hepatology</i> , 2013, 57, 1716-1724.	3.6	16
88	Hepatitis C virus NS5B polymerase primes innate immune signaling. <i>Hepatology</i> , 2013, 57, 1275-1277.	3.6	2
89	Hepatitis C Virus p7 is Critical for Capsid Assembly and Envelopment. <i>PLoS Pathogens</i> , 2013, 9, e1003355.	2.1	102
90	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. <i>Journal of Infectious Diseases</i> , 2013, 208, 1943-1952.	1.9	47

#	ARTICLE	IF	CITATIONS
91	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. <i>Journal of Infectious Diseases</i> , 2013, 207, 281-287.	1.9	57
92	Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment. <i>Journal of Virology</i> , 2013, 87, 13297-13306.	1.5	18
93	Subcellular Localization and Function of an Epitope-Tagged p7 Viroprotein in Hepatitis C Virus-Producing Cells. <i>Journal of Virology</i> , 2013, 87, 1664-1678.	1.5	42
94	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. <i>Hepatology</i> , 2013, 57, 492-504.	3.6	66
95	Interferon $\gamma$ -Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012, 205, 1351-1362.	1.9	38
96	MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles. <i>PLoS Pathogens</i> , 2012, 8, e1002829.	2.1	110
97	Escape from a Dominant HLA-B*15-Restricted CD8 <sup>+</sup> T Cell Response against Hepatitis C Virus Requires Compensatory Mutations outside the Epitope. <i>Journal of Virology</i> , 2012, 86, 991-1000.	1.5	21
98	High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants. <i>Journal of Biological Chemistry</i> , 2012, 287, 39224-39232.	1.6	20
99	Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors. <i>Journal of Visualized Experiments</i> , 2012, , e4029.	0.2	0
100	A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. <i>Gastroenterology</i> , 2012, 143, 213-222.e5.	0.6	111
101	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. <i>Gastroenterology</i> , 2012, 143, 223-233.e9.	0.6	66
102	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. <i>Gastroenterology</i> , 2012, 143, 439-447.e1.	0.6	30
103	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , 2012, 96, 51-58.	1.9	2
104	Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus. <i>PLoS ONE</i> , 2012, 7, e45770.	1.1	15
105	Total Synthesis of a Noricumazole...A Library and Evaluation of HCV Inhibition. <i>Chemistry - A European Journal</i> , 2012, 18, 9083-9090.	1.7	19
106	Bile Acids Specifically Increase Hepatitis C Virus RNA-Replication. <i>PLoS ONE</i> , 2012, 7, e36029.	1.1	23
107	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. <i>Nature Medicine</i> , 2011, 17, 589-595.	15.2	631
108	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. <i>Journal of Viral Hepatitis</i> , 2011, 18, 562-570.	1.0	24

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. <i>Antiviral Research</i> , 2011, 89, 136-148.	1.9	41
110	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011, 54, 1947-1955.	3.6	255
111	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	1.5	40
112	Prolonged Survival of Hepatitis C Virus in the Anesthetic Propofol. <i>Clinical Infectious Diseases</i> , 2011, 53, 963-964.	2.9	11
113	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. <i>PLoS Pathogens</i> , 2011, 7, e1002029.	2.1	23
114	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. <i>Journal of Infectious Diseases</i> , 2011, 204, 1830-1838.	1.9	90
115	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. <i>PLoS ONE</i> , 2011, 6, e24142.	1.1	9
116	Development of novel therapies for hepatitis C. <i>Antiviral Research</i> , 2010, 86, 79-92.	1.9	70
117	NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus. <i>Journal of Biological Chemistry</i> , 2010, 285, 31446-31461.	1.6	119
118	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. <i>Journal of Virology</i> , 2010, 84, 5751-5763.	1.5	201
119	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 63-79.	1.4	8
120	Mouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell Line. <i>Journal of Virology</i> , 2010, 84, 964-975.	1.5	50
121	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. <i>Journal of Infectious Diseases</i> , 2010, 201, 1859-1866.	1.9	72
122	Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. <i>PLoS Pathogens</i> , 2010, 6, e1000978.	2.1	109
123	Hepatitis C Virus P7â€”A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy. <i>Viruses</i> , 2010, 2, 2078-2095.	1.5	44
124	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1875-1884.	0.6	68
125	Interferon-Î±-Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	0.6	177
126	Virucidal activity of 2 alcohol-based formulations proposed as hand rubs by the World Health Organization. <i>American Journal of Infection Control</i> , 2010, 38, 66-68.	1.1	34



#	ARTICLE	IF	CITATIONS
127	Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations. <i>PLoS Pathogens</i> , 2009, 5, e1000475.	2.1	116
128	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. <i>Journal of Biological Chemistry</i> , 2009, 284, 17657-17667.	1.6	79
129	Characterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using trans -Complementation. <i>Journal of Virology</i> , 2009, 83, 11682-11693.	1.5	65
130	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 295-308.	7.7	345
131	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 447.	7.7	1
132	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009, 50, 1638-1645.	3.6	108
133	Final entry key for hepatitis C. <i>Nature</i> , 2009, 457, 797-798.	13.7	28
134	Regulation of hepatitis C virus replication by microRNAs. <i>Journal of Hepatology</i> , 2009, 50, 441-444.	1.8	14
135	Full-Length Infectious HCV Chimeras. <i>Methods in Molecular Biology</i> , 2009, 510, 347-359.	0.4	8
136	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. <i>Journal of General Virology</i> , 2009, 90, 48-58.	1.3	162
137	Efficient <i>trans</i> -Encapsidation of Hepatitis C Virus RNAs into Infectious Virus-Like Particles. <i>Journal of Virology</i> , 2008, 82, 7034-7046.	1.5	131
138	Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly. <i>Journal of Biological Chemistry</i> , 2008, 283, 28546-28562.	1.6	135
139	The Suppressive Effect That Myriocin Has on Hepatitis C Virus RNA Replication Is Independent of Inhibition of Serine Palmitoyl Transferase. <i>Journal of Infectious Diseases</i> , 2008, 198, 1091-1093.	1.9	6
140	Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. <i>PLoS Pathogens</i> , 2007, 3, e103.	2.1	290
141	Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes. <i>Journal of Virology</i> , 2007, 81, 4591-4603.	1.5	198
142	The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells. <i>Journal of Virology</i> , 2007, 81, 588-598.	1.5	201
143	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. <i>Hepatology</i> , 2007, 46, 330-338.	3.6	127
144	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. <i>Hepatology</i> , 2007, 46, 1722-1731.	3.6	222

#	ARTICLE	IF	CITATIONS
145	High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI. <i>Journal of Biological Chemistry</i> , 2006, 281, 18285-18295.	1.6	186
146	HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. <i>Journal of Hepatology</i> , 2006, 45, 5-12.	1.8	46
147	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. <i>Hepatology</i> , 2006, 43, 592-601.	3.6	150
148	Characterization of the Prototype Foamy Virus Envelope Glycoprotein Receptor-Binding Domain. <i>Journal of Virology</i> , 2006, 80, 8158-8167.	1.5	21
149	Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses. <i>Journal of Virology</i> , 2006, 80, 5308-5320.	1.5	363
150	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7408-7413.	3.3	651
151	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. <i>Nature Medicine</i> , 2005, 11, 791-796.	15.2	2,561
152	Efficient hepatitis C virus cell culture system: What a difference the host cell makes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9739-9740.	3.3	91
153	Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain. <i>Journal of Virology</i> , 2005, 79, 3187-3194.	1.5	208
154	Targeting of Hepatitis C Virus Core Protein to Mitochondria through a Novel C-Terminal Localization Motif. <i>Journal of Virology</i> , 2004, 78, 7958-7968.	1.5	144
155	Prototype Foamy Virus Envelope Glycoprotein Leader Peptide Processing Is Mediated by a Furin-Like Cellular Protease, but Cleavage Is Not Essential for Viral Infectivity. <i>Journal of Virology</i> , 2004, 78, 13865-13870.	1.5	49
156	Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs. <i>Journal of Virology</i> , 2004, 78, 3436-3446.	1.5	158
157	Application of the trak-Câ„¢ HCV core assay for monitoring antiviral activity in HCV replication systems. <i>Journal of Virological Methods</i> , 2004, 118, 23-31.	1.0	17
158	Novel Insights into Hepatitis C Virus Replication and Persistence. <i>Advances in Virus Research</i> , 2004, 63, 71-180.	0.9	243
159	Hepatitis C Virus Replication in Cell Culture. , 2004, , 108-122.		0
160	Determinants of foamy virus envelope glycoprotein mediated resistance to superinfection. <i>Virology</i> , 2003, 314, 243-252.	1.1	20
161	Tissue culture and animal models for hepatitis C virus. <i>Clinics in Liver Disease</i> , 2003, 7, 23-43.	1.0	29
162	Replication-Competent Hybrids between Murine Leukemia Virus and Foamy Virus. <i>Journal of Virology</i> , 2003, 77, 7677-7681.	1.5	6

#	ARTICLE	IF	CITATIONS
163	Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture. <i>Journal of Virology</i> , 2002, 76, 4008-4021.	1.5	330
164	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14416-14421.	3.3	244
165	A Particle-Associated Glycoprotein Signal Peptide Essential for Virus Maturation and Infectivity. <i>Journal of Virology</i> , 2001, 75, 5762-5771.	1.5	112
166	Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs. <i>Journal of Virology</i> , 2001, 75, 1252-1264.	1.5	336
167	Interferon- $\beta$ inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. <i>Journal of General Virology</i> , 2001, 82, 723-733.	1.3	210
168	Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. <i>EMBO Journal</i> , 2000, 19, 3436-3445.	3.5	38
169	An Evolutionarily Conserved Positively Charged Amino Acid in the Putative Membrane-Spanning Domain of the Foamy Virus Envelope Protein Controls Fusion Activity. <i>Journal of Virology</i> , 2000, 74, 4474-4482.	1.5	54
170	Specific Binding of Recombinant Foamy Virus Envelope Protein to Host Cells Correlates with Susceptibility to Infection. <i>Virology</i> , 1999, 255, 228-236.	1.1	19
171	Foamy Virus Capsids Require the Cognate Envelope Protein for Particle Export. <i>Journal of Virology</i> , 1999, 73, 2613-2621.	1.5	152